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Cells of the human umbilical cord offer tremendous
potential for improving human health. Cells from the
Wharton’s jelly (umbilical cord stroma) in particular,
referred to as human umbilical cord mesenchymal
stromal cells (HUCMSCs), hold several advantages that
make them appealing for translational research. In the
previous issue of Stem Cell Research & Therapy, Chon
and colleagues made an important contribution to the
HUCMSC literature not only by presenting HUCMSCs as
an emerging cell source for intervertebral disc
regeneration in general and the nucleus pulposus in
particular, but also by demonstrating that an
extracellular matrix-based strategy might be preferred
over the use of growth factors. By culturing HUCMSCs
under hypoxia in serum-free conditions in the presence
of Matrigel with laminin-111, they were able to achieve
intense collagen II staining by 21 days without the
addition of exogenous growth factors. There is
tremendous translational significance here in that such
raw materials may alleviate the need for the use of
growth factors in some instances, and this may have
important ramifications in reducing product cost and
streamlining regulatory approval. Chon and colleagues
provide a promising example of the potential of
HUCMSCs, demonstrating the ability to guide HUCMSC
differentiation even in the absence of serum and
growth factors and supporting the use of HUCMSCs as
a viable alternative in intervertebral disc regeneration.Correspondence: detamore@ku.edu
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© BioMed Central Ltd.2013Cells from the human umbilical cord offer tremendous
potential for improving human health. Although the um-
bilical cord blood and even the endothelial cells from
the umbilical cord vein have captured most of our atten-
tion, the bulk of the umbilical cord - that is, the stroma
(also known as Wharton’s jelly) - is a mesenchymal cell
source with tremendous potential. These cells have been
referred to as human umbilical cord mesenchymal stro-
mal cells (HUCMSCs), Wharton’s jelly cells, and human
umbilical cord stroma-derived mesenchymal stem cells.
In the previous issue of Stem Cell Research & Therapy,
Chon and colleagues [1] made an important contribu-
tion to the HUCMSC literature not only by presenting
HUCMSCs as an emerging cell source for intervertebral
disc (IVD) regeneration in general and the nucleus pul-
posus in particular, but also by demonstrating that an
extracellular matrix-based strategy might potentially sur-
pass a growth factor-based strategy.
HUCMSCs have been generating a tremendous level
of interest, especially in the last 10 years [2]. Following
pioneering studies on the differentiation potential of
HUCMSCs, these cells were introduced to the three-
dimensional musculoskeletal tissue engineering literature
in 2007 [3]. Since then, their use has exploded in muscu-
loskeletal tissue engineering [4] as an alternative to other
popular mesenchymal cell sources such as bone marrow
and adipose tissue. Within the musculoskeletal realm,
investigators have only recently turned their attention
with HUCMSCs to the IVD [5,6].
In their study of HUCMSCs for the IVD, Chon and col-
leagues pooled HUCMSCs from three donors and seeded
them on top of Transwell inserts pre-coated with laminin-
111-containing Matrigel. The ‘pseudo-three-dimensional’
aspect of their study came from the incorporation of a
2.5% Matrigel solution rich in laminin-111 into serum-
free medium. This medium composition represented their
control group, which was compared with groups that con-
tained either transforming growth factor (TGF)-β1 or
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groups were cultured under hypoxia (2% O2), as others
have previously shown that hypoxia clearly influences
HUCMSCs [7], an important point for others considering
the use of HUCMSCs in regenerative medicine.
The most exciting result, in my opinion, was that
Chon and colleagues were able to achieve intense colla-
gen II staining in their control group, as can be seen in
Figure four of their article. Generally, they observed no
clear improvement in nucleus pulposus-like phenotype
for HUCMSCs with the addition of growth factors to
their laminin-111-containing Matrigel system. Although
it would be interesting to tease out whether it was the
hypoxia or the laminin-111 (or their combination with
each other or some other factor or both) that led to this
result, it was very encouraging to see the emergence of
collagen II staining over the 21-day period of the study,
given the challenges with collagen II expression that
have been observed in the past [8]. The collagen II stain-
ing in the control group was arguably more intense than
even the group containing TGF-β1, although it should
be noted that the TGF-β1 group led to higher aggrecan
gene expression than the control. More specific to the
nucleus pulposus, it was also encouraging to see that the
HUCMSCs expressed extracellular matrix proteins of
laminin α5 as well as laminin receptors (integrin α3 and
β4 subunits).
Favorable collagen II staining in the absence of growth
factors as observed by Chon and colleagues may lend
credibility to the emerging philosophy that extracellular
matrix molecules, in addition to being valuable building
blocks or ‘raw materials’ in regenerative medicine, might
prove to be valuable signaling molecules [9]. There is
tremendous translational significance here, in that such
raw materials might alleviate the need for the use of
growth factors in some instances, and this may have im-
portant ramifications in reducing product cost and
streamlining regulatory approval.
As our field moves forward with HUCMSCs in IVD
and other musculoskeletal applications and beyond,
there are a few considerations to take into account. First,
HUCMSCs are a heterogeneous population. Following
the work that has been done in the bone marrow com-
munity with identifying mesenchymal stem cell clones
with chondrogenic potential [10] might be valuable for
applications such as the IVD. In addition, banking of
HUCMSCs [11] is becoming a viable option as compan-
ies are entering this market, in which there are two busi-
ness models: one to collect autologous cells for a child
at a cost to the parents, and another to collect cells for
allogeneic banking, perhaps to use in a tissue-typing ap-
plication. Although there is evidence that HUCMSCs
might be tolerated in allogeneic transplantation [12],
there is the concern that HUCMSCs might experience aloss in their immunosuppressive or immunotolerant
character upon differentiation, as has been observed
with mesenchymal cells from bone marrow [13]. How-
ever, there is recent evidence that HUCMSCs may retain
favorable immunocompatibility after differentiation
[14,15].
HUCMSCs offer numerous advantages, including mul-
tipotency, low cost, availability, commercial relevance
and availability of banking, absence of donor site mor-
bidity, political neutrality, high passage potential, and
potential immunocompatibility following differentiation
[4]. Chon and colleagues provide us another example of
the limitless possibilities with HUCMSCs, underscoring
the opportunity to guide HUCMSC differentiation even
in the absence of serum and growth factors and further
supporting the role of HUCMSCs as a promising cell
source for IVD regeneration.
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